The Damaging Impact of PDUFA and Why It Should be Repealed
The re-prioritization of rapid approvals occurred at the expense of drug safety standards,
-
-
Role of Litigation in Defining Drug Risks_JAMA / BMJ
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
-
Critique of FDA’s latest SSRI Data Analysis
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
-
Negative Research Results–Mostly Concealed in Journals_SharonBegley, WSJ
"Why are scientists coy about publishing negative data?
-
Antipsychotics, Newer Isn’t BetterDrug_Washington Post front page
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
-
NEJM Vioxx Safety Correction / Consumers International Accuses Industry–Unscrupulous Marketing
Once again, the New England Journal of Medicine (July 13, 2006) has had to eat crow after it published false and misleading clinical trial findings.
-
Intermittent Explosive Disorder-a parody
It is difficult to believe this latest announcement laying claim to a new "under treated" psychiatric disorder–Intermittent Explosive Disorder (IED) is not a parody !!
-
Real-Life Epilogue To “Erin Brockovich”: Medical Journal Retracts Fraudulent Chromium/Cancer Study
The Journal of Occupational and Environmental Medicine (JOEM) has published a retraction of a 1997 fraudulent article claiming chromium does not cause
cancer. -
Trial Analyst Finds Embarassing Inconsistencies in NIMH Flawed Safety Study
GSK’s acknowledgement refutes the recent claims made in the official organ of the American Psychiatric Association, The American Journal of Psychiatry.
-
FDA Psychopharm Advisory Chair Acknowledges No Evidence for SSRI Chemical Imbalance Claims_CMAJ
"Biological psychiatrists have looked very closely for a serotonin imbalance or dysfunction in patients with depression or obsessive compulsive disorder and, to date, it has been elusive," says Dr. Wayne Goodman, Chair of the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee.